Team Sahi
Wakefit Innovations IPO closed its subscription window on December 10, 2025. The public issue comprised a fresh issue of ₹377 crore along with an offer for sale (OFS) of approximately ₹911 crore, aggregating to a total issue size of ₹1,289 crore. The price band for the IPO was fixed at ₹185–₹195 per share.
The basis of allotment is expected on December 11, 2025, with refunds and demat credit scheduled for December 12, while the shares are likely to list on December 15, 2025 on both NSE and BSE.
Wakefit Innovations Limited is a Bengaluru-based direct-to-consumer (D2C) brand offering end-to-end home and sleep solutions. The company focuses on mattresses, furniture, and home furnishings, operating through an omni-channel model across online platforms, offline stores, and third-party marketplaces in India.
Registrar: MUFG Intime India Pvt. Ltd.
| Investor Category | Subscription (Times) |
|---|---|
| Qualified Institutional Buyers (QIBs) | 3.04× |
| HNIs | 1.05× |
| Retail Individual Investors (RII) | 3.17× |
| Total | 2.52× |
Wakefit Innovations Limited is a vertically integrated consumer lifestyle brand operating in the home and sleep solutions segment. Its product portfolio includes mattresses, furniture, furnishings, and home décor, catering to mass, masstige, and premium customer segments.
The company follows a strong omni-channel strategy, selling through its own website, offline COCO stores, and leading online marketplaces, and has served over 2 million customers across India.
On the financial front, Wakefit reported FY25 revenue of approximately ₹1,273 crore, marking a strong increase from ₹986 crore in FY24. The company posted EBITDA of ₹91 crore, reflecting 38% year-on-year growth, though it reported a net loss of ₹35 crore during the year as it continued to invest in expansion and brand building.
Related
Recent
Fed's 2026 Outlook: Economic Resilience Meets Persistent Inflationary Pressures
Geopolitical Brinkmanship: Trump-Iran Tensions and the Indian Market Outlook
Zydus Lifesciences Disrupts Respiratory Care with India’s First Drug-Free Device 'Pepair' at ₹990
Infosys Pivots to 'AI-First' Era: New Framework Targets $300 Billion Market Opportunity
Zydus Lifesciences Disrupts Respiratory Care with India’s First Affordable Drug-Free Device ‘PepairTM’ at ₹990